Here, the authors investigate triplet combination of sitravatinib with nivolumab and ipilimumab (anti-CTLA4) in patients with metastatic ccRCC and longitudinal single-cell transcriptomic analysis. This evidence concerns the gene CTLA4 and nonpapillary renal cell carcinoma.